Disseminated intravascular coagulation in hematologic malignancies

Area of Science:

• Hematology
• Oncology
• Coagulation Science

Background:

• Disseminated intravascular coagulation (DIC) is a significant cause of bleeding and thrombotic complications in patients with hematologic malignancies.
• A prothrombotic state, characterized by chronic or subclinical DIC, is often detectable due to coagulation system activation.
• Disease and treatment factors can exacerbate thrombosis or bleeding risks, further triggering DIC mechanisms.

Purpose of the Study:

• To review coagulation abnormalities, clinical manifestations, and pathophysiologic mechanisms of DIC in hematologic malignancies.
• To focus on the extensively studied condition of acute promyelocytic leukemia (APL).
• To discuss current management and treatment approaches and identify open issues.

Main Methods:

• Literature review of coagulation abnormalities in hematologic malignancies.
• Analysis of clinical manifestations and pathophysiologic mechanisms of DIC.
• Focus on acute promyelocytic leukemia (APL) as a primary model.

Main Results:

• Overt DIC occurs in approximately 15% of acute leukemia patients, with bleeding complications being more prevalent than thrombosis.
• Bleeding manifestations have the most severe clinical impact in acute promyelocytic leukemia (APL).
• Malignant cells possess intrinsic properties that activate coagulation, and chemotherapy or infections play concurrent roles.

Conclusions:

• DIC is a critical complication in hematologic malignancies, particularly APL, with complex underlying mechanisms.
• Understanding these mechanisms is crucial for developing effective management and treatment strategies.
• Further research is needed to address open issues in DIC management for these patients.